nach oben

Journal of Radiation Oncology

Erschienen in:

03.07.2017 | Original Research

Analysis of treatment effectiveness and complications associated with MammoSite™ breast brachytherapy in patients treated at a single institution

Erschienen in: Journal of Radiation Oncology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Objective

The objective of the study was to present treatment and follow-up data over a 5-year period for patients treated with MammoSite™ breast brachytherapy at our institution. Patient data was collected regarding the specific treatment and planning volumes, the complications occurring during and after treatment, and the overall outcome of each patient relating to tumor-free survival.

Methods

We performed a retrospective analysis of patients who presented with early stage breast cancer and received breast conserving surgery. These patients elected to receive accelerated partial breast irradiation (APBI) using the MammoSite™ catheter device. Patients were treated with 30.6–34.0 Gy in 3.4 Gy fractions twice daily with a minimum of 6 h between fractions utilizing either a spherical or an ellipsoidal catheter device.

Results

From October 2005 to November 2010, 78 patients eligible for our retrospective analysis were treated with APBI using the MammoSite™ catheter device. The median follow-up time was 80 months. Of the patients in our study, there were a total of 10 recurrences. Five of these recurrences were local, two of the recurrences were local or new primaries that eventually developed into widespread metastatic disease, and three of the recurrences were widespread metastatic disease. Two were considered new primaries due to receptor status change in the new tumor.

Conclusions

This case series of 78 patients having greater than 24 months of follow-up from a single institution provides important data regarding failure analysis with MammoSite™ accelerated partial breast irradiation. Our results show a higher rate of metastatic recurrence in the group of patients with positive nodal disease.

Arthur DW et al (2008) A phase II trial of brachytherapy alone after lumpectomy for select breast cancer: tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys 72(2):467–473CrossRefPubMedCentralPubMed

Abbott AM, Habermann EB, Tuttle TM (2011) Trends in the use of implantable accelerated partial breast irradiation therapy for early stage breast cancer in the United States. Cancer 117(15):3305–3310CrossRefPubMed

Fisher B et al (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241CrossRefPubMed

Morrow M et al (2001) Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol 19(8):2254–2262CrossRefPubMed

Vicini F et al (2011) Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 79(3):808–817CrossRefPubMed

Vicini F et al (2008) Three-year analysis of treatment efficacy, cosmesis, and toxicity by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation (APBI). Cancer 112(4):758–766CrossRefPubMed

Dickler A et al (2004) Treatment volume and dose optimization of MammoSite breast brachytherapy applicator. Int J Radiat Oncol Biol Phys 59(2):469–474CrossRefPubMed

Kirk M et al (2005) Surface optimization technique for MammoSite breast brachytherapy applicator. Int J Radiat Oncol Biol Phys 62(2):366–372CrossRefPubMed

Chen S et al (2007) Patterns of failure after MammoSite brachytherapy partial breast irradiation: a detailed analysis. Int J Radiat Oncol Biol Phys 69(1):25–31CrossRefPubMed

10.

McHaffie DR et al (2011) Outcomes after accelerated partial breast irradiation in patients with ASTRO consensus statement cautionary features. Int J Radiat Oncol Biol Phys 81(1):46–51CrossRefPubMed

11.

Smith BD et al (2009) Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). J Am Coll Surg 209(2):269–277CrossRefPubMed

12.

Correa, C. et al (2016) Accelerated partial breast irradiation: Executive summary for the update of an ASTRO Evidence-Based Consensus Statement. Pract Radiat Oncol

13.

Chao KK et al (2007) Analysis of treatment efficacy, cosmesis, and toxicity using the MammoSite breast brachytherapy catheter to deliver accelerated partial-breast irradiation: the William Beaumont Hospital experience. Int J Radiat Oncol Biol Phys 69(1):32–40CrossRefPubMed

14.

Khan AJ et al (2012) Six-year analysis of treatment-related toxicities in patients treated with accelerated partial breast irradiation on the American Society of Breast Surgeons MammoSite Breast Brachytherapy registry trial. Ann Surg Oncol 19(5):1477–1483CrossRefPubMed

15.

Yashar CM et al (2011) Initial clinical experience with the Strut-Adjusted Volume Implant (SAVI) breast brachytherapy device for accelerated partial-breast irradiation (APBI): first 100 patients with more than 1 year of follow-up. Int J Radiat Oncol Biol Phys 80(3):765–770CrossRefPubMed

16.

Dragun AE et al (2007) Predictors of cosmetic outcome following MammoSite breast brachytherapy: a single-institution experience of 100 patients with two years of follow-up. Int J Radiat Oncol Biol Phys 68(2):354–358CrossRefPubMed

17.

Brashears JH, Dragun AE, Jenrette JM (2009) Late chest wall toxicity after MammoSite breast brachytherapy. Brachytherapy 8(1):19–25CrossRefPubMed

18.

Cuttino LW et al (2014) Long-term results from the Contura multilumen balloon breast brachytherapy catheter phase 4 registry trial. Int J Radiat Oncol Biol Phys 90(5):1025–1029CrossRefPubMed

19.

Yashar C et al (2016) Strut-based accelerated partial breast irradiation: report of treatment results for 250 consecutive patients at 5 years from a multicenter retrospective study. Brachytherapy 15(6):780–787CrossRefPubMed

20.

Wolmark N et al. (2011) NSABP protocol B-39/RTOG protocol 0413: a randomized phase III study of conventional whole breast irradiation (WBI) versus partial breast irradiation (PBI) for women with stage 0, I, or II breast cancer

21.

Offersen BV et al (2009) Accelerated partial breast irradiation as part of breast conserving therapy of early breast carcinoma: a systematic review. Radiother Oncol 90(1):1–13CrossRefPubMed

22.

Julian T et al (2011) Updated Early Toxicity Results with 3-D Conformal External Beam Therapy (CRT) from the NSABP B-39/RTOG 0413 Accelerated Partial Breast Irradiation (APBI) Trial. In: ASCO Annual Meeting. doi:10.1200/jco.2011.29.15_suppl.1011

23.

Benitez PR et al (2007) Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg 194(4):456–462CrossRefPubMed

24.

Shah C et al (2011) Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol 100(2):210–214CrossRefPubMed

25.

Beitsch PD et al (2012) Tumor bed control with balloon-based accelerated partial breast irradiation: incidence of true recurrences versus elsewhere failures in the American Society of Breast Surgery MammoSite(®) Registry Trial. Ann Surg Oncol 19(10):3165–3170CrossRefPubMed

26.

Haley M et al (2009) MammoSite accelerated partial breast irradiation: a single-institution outcomes analysis with 2 years of followup. Brachytherapy 8(1):9–13CrossRefPubMed

27.

DiFronzo LA et al (2005) Breast conserving surgery and accelerated partial breast irradiation using the MammoSite system: initial clinical experience. Arch Surg 140(8):787–794CrossRefPubMed

28.

Niehoff P et al (2006) Clinical experience with the MammoSite radiation therapy system for brachytherapy of breast cancer: results from an international phase II trial. Radiother Oncol 79(3):316–320CrossRefPubMed

29.

Niehoff P et al (2006) Early European experience with the MammoSite radiation therapy system for partial breast brachytherapy following breast conservation operation in low-risk breast cancer. Breast 15(3):319–325CrossRefPubMed

30.

Sadeghi A et al (2006) Evaluation of the surface radiation dose and dose gradient in early stage breast cancer using high-dose-rate brachytherapy MammoSite applicator. Brachytherapy 5(4):230–234

31.

Tsai PI et al (2006) Accelerated partial breast irradiation using the MammoSite device: early technical experience and short-term clinical follow-up. Am Surg 72(10):929–934PubMed

32.

Beitsch P et al (2010) Five-year outcome of patients classified in the "unsuitable" category using the American Society of Therapeutic Radiology and Oncology (ASTRO) Consensus Panel guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite® Registry trial. Ann Surg Oncol 17(Suppl 3):219–225CrossRefPubMed

33.

Harper JL et al (2005) Acute complications of MammoSite brachytherapy: a single institution's initial clinical experience. Int J Radiat Oncol Biol Phys 61(1):169–174CrossRefPubMed

34.

Cuttino LW et al (2008) Multi-institutional experience using the MammoSite radiation therapy system in the treatment of early-stage breast cancer: 2-year results. Int J Radiat Oncol Biol Phys 71(1):107–114CrossRefPubMed

35.

Rosenkranz KM et al (2013) Increased rates of long-term complications after MammoSite brachytherapy compared with whole breast radiation therapy. J Am Coll Surg 217(3):497–502CrossRefPubMed

Titel: Analysis of treatment effectiveness and complications associated with MammoSite™ breast brachytherapy in patients treated at a single institution
Publikationsdatum: 03.07.2017
Erschienen in: Journal of Radiation Oncology / Ausgabe 4/2017
Print ISSN: 1948-7894
Elektronische ISSN: 1948-7908
DOI: https://doi.org/10.1007/s13566-017-0320-9

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Analysis of treatment effectiveness and complications associated with MammoSite™ breast brachytherapy in patients treated at a single institution

Abstract

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Maximizing survival in patients with muscle-invasive bladder cancer undergoing curative bladder-preserving radiotherapy: the impact of radiotherapy dose escalation

Fractionation trends in breast cancer and implications in partial breast irradiation

Liver stereotactic radiotherapy (SRT) with functional treatment planning for patients with intermediate stage hepatocellular carcinoma (HCC)

Active monitoring in non-invasive breast cancer: insight gained from a large national database

Hemostatic radiotherapy in advanced bladder cancer: a single-institution experience

Intratumoral treatment with radioactive beta-emitting microparticles: a systematic review

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie